🇺🇸 FDA

Company profile · Sponsor

Maze

Maze Therapeutics

MAZE · NYSE biotech SOUTH SAN FRANCISCO, CA, USA
Pipeline
8
Drugs
0
Patents
8

Quick answer

Maze (MAZE) is a biotech company. headquartered in SOUTH SAN FRANCISCO, CA, USA. listed on NYSE. NovaPharmaNews links 8 pipeline programs, 0 drugs, and 8 patents to this profile..

Company facts

Ticker MAZE
Exchange NYSE
Company type biotech
Headquarters SOUTH SAN FRANCISCO, CA, USA
SEC CIK 0001842295

Pipeline (8)

Search pipeline →

  1. 0.9% w/v sodium chloride solution for intravenous infusion, Panzyga 100 mg/ml Infusionslösung

    Maze

    Pediatric acute-onset neuropsychiatric syndrome (PANS)

    phase 3 small molecule active

    1 trial

  2. Isotone Kochsalz-Lösung 0,9 % Braun Infusionslösung, C1-esterase inhibitor

    Maze

    acute hereditary angioedema attacks

    phase 3 small molecule active

    1 trial

  3. Isotone Kochsalz-Lösung 0,9 % Braun Infusionslösung, Panzyga 100 mg/ml Infusionslösung

    Maze

    Primary infection prophylaxis in patients with chronic lymphocytic leukemia (CLL) and secondary hypogammaglobulinemia.

    phase 3 small molecule active

    1 trial

  4. Newnorm

    Maze

    Human Normal Immunoglobulin

    phase 3 small molecule active

    1 trial

  5. Panzyga 100 mg/ml Infusionslösung, Isotone Kochsalz-Lösung 0,9 % Braun Infusionslösung

    Maze

    Prevention of a Major infection in patients with Hypogammaglobulinemia and Autoimmune or Rheumatic Conditions receiving treatment with B-cell depletion therapy.

    phase 3 small molecule active

    1 trial

  6. MZE829

    Maze

    Proteinuric Kidney Disease

    phase 2 small molecule active

    1 trial

  7. MZE829

    Maze

    APOL1 Kidney Disease (AKD)

    phase 2 small molecule active

    1 trial

  8. MZE001

    Maze

    Healthy

    phase 1 small molecule completed

    1 trial

Patents (8)

Search patents →

  1. US 12310943

    Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders

    Expires Mon May 22 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12297182

    Compositions comprising an urolithin compound

    Expires Mon May 08 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12226455

    Medical composition for treating cardiac wasting and cachexia

    Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12220424

    Compositions comprising nicotinamide riboside and a urolithin

    Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12109190

    Urolithins as immune response enhancers

    Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12036205

    Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders

    Expires Mon Jul 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12030863

    Prodrugs of urolithins and uses thereof

    Expires Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11969408

    Method for improving mitophagy in subjects

    Expires Mon Apr 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Maze?

Maze (MAZE) is a biotech company. headquartered in SOUTH SAN FRANCISCO, CA, USA. listed on NYSE. NovaPharmaNews links 8 pipeline programs, 0 drugs, and 8 patents to this profile..

What pipeline programs does Maze sponsor?

We track 8 ClinicalTrials.gov-linked programs for Maze, including 0.9% w/v sodium chloride solution for intravenous infusion, Panzyga 100 mg/ml Infusionslösung and 7 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Maze company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.